Sign In
Buy DSGN
$12.18
-0.440 (-3.49%)
At Close: Jul 31, 2026
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
04:01pm, Monday, 21'st Apr 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
08:00am, Thursday, 17'th Apr 2025
CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 12'th Mar 2025
Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025
Design Therapeutics to Participate in Leerink's Global Healthcare Conference
08:00am, Monday, 03'rd Mar 2025
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
08:00am, Wednesday, 13'th Nov 2024
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
04:01pm, Thursday, 07'th Nov 2024
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healt
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
10:55am, Wednesday, 21'st Aug 2024
The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
08:00am, Monday, 05'th Aug 2024
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains
08:50pm, Wednesday, 22'nd May 2024
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
04:05pm, Wednesday, 08'th May 2024
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Current
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
06:30am, Tuesday, 07'th May 2024
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced th
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript
08:44pm, Tuesday, 19'th Mar 2024
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Tuesday, 19'th Mar 2024
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
06:30am, Tuesday, 12'th Mar 2024
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced
